Galena reports positive results from Phase I/IIa cancer trial of GALE-301

US-based biopharmaceutical firm Galena Biopharma has reported positive final results from the Phase I/IIa clinical trial of GALE-301 (E39) to prevent recurrence of ovarian and endometrial cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news